#### Wastewater testing during the South African 2022-2023 1

#### measles outbreak demonstrates the potential of 2

#### environmental surveillance to support measles elimination 3

4 Nkosenhle Ndlovu<sup>1</sup>, Victor Mabasa<sup>1</sup>, Chenoa Sankar<sup>1</sup>, Nosihle Msomi<sup>1</sup>, Emmanuel Phalane<sup>1</sup>, Natasha Singh<sup>1</sup>, Sipho Gwala<sup>1</sup>, Fiona Els<sup>1,2,4</sup>, Mokgaetji Macheke<sup>1</sup>, Sibonginkosi Maposa<sup>1</sup>, and Mukhlid 5

- Yousif<sup>¶1,3</sup>, Kerrigan M. McCarthy<sup>\*¶1,3,4</sup> 6
- 7
- <sup>1</sup>Wastewater Genomics, Centre for Vaccines and Immunology, National Institute for Communicable 8
- 9 Diseases, Johannesburg, Gauteng, South Africa,
- 10 <sup>2</sup>Gauteng City-Region Observatory (GCRO), Gauteng, South Africa,
- <sup>3</sup>Department of Virology, School of Pathology, Faculty of Health Sciences, University of 11
- Witwatersrand, Johannesburg, Gauteng, South Africa. 12
- 13 <sup>4</sup> School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg,
- Gauteng, South Africa. 14
- 15
- 16 <sup>¶</sup>These authors contributed equally to this work
- 17
- 18 \*Corresponding author
- 19 Address: Centre for Vaccines and Immunology, National Institute for Communicable Diseases, 1
- Modderfontein Rd, Sandringham, Johannesburg, 2192, South Africa. 20
- E-mail: kerriganm@nicd.ac.za 21
- 22

#### 23 **Author contributions**

Name (Abbreviation)	Contributions	ORCID ID
Nkosenhle Ndlovu (NN)	Data curation, Formal analysis,	
	Investigation, Writing - original draft	
Victor Mabasa (VM)	Conceptualisation, Formal analysis,	0000-0002-0564-0344
	Investigation, Methodology, Project	
	administration, Resources, Software,	
	Validation, Writing – review and	
NOTE: This preprint reports new research that	t has not been certified by peer review and should not b	e used to guide clinical practice.

Chenoa Sankar (CS)	Data curation, Formal analysis,	0009-0007-7869-2026
	Investigation, Methodology, Software,	
	Writing – review and editing	
Nosihle Msomi (NM)	Data curation, Formal analysis,	0000-0003-0053-0928
	Investigation, Software, Writing -	
	review and editing	
Emmanuel Phalane (EP)	Data curation, Investigation, Writing -	0000-0003-1208-3037
	review and editing	
Natasha Singh (NS)	Investigation, Writing – review and	0000-0003-3074-8303
	editing	
Sipho Gwala (SG)	Investigation, Writing – review and	0000-0002-8912-5584
	editing	
Fiona Els (FE)	Writing – review and editing	0000-0002-4169-
		813X
Mokgaetji Macheke (MM)	Investigation, Writing – review and	0000-0002-5179-8230
	editing	
Sibonginkosi Maposa (SM)	Investigation, Project administration,	0000-0003-0575-1420
	Resources, Supervision, Writing -	
	review and editing	
Mukhlid Yousif (MY)	Conceptualisation, Funding	0000-0002-8707-2255
	acquisition, Methodology, Supervision	
	Validation, Writing – review and	
	editing	
Kerrigan McCarthy (KM)	Conceptualisation, Funding	0000-0001-8958-9795
	acquisition, Formal analysis,	
	Methodology, Supervision, Validation,	
	Writing original draft, Writing –	
	review and editing	

24

## 25 Abstract

### 26 Background

- 27 Sensitive clinical surveillance and high vaccination coverage are required to meet the WHO 2030
- 28 measles elimination target. Whilst wastewater and environmental surveillance (WES) has proven
- 29 usefulness in polio surveillance, it has not been applied to measles control. We describe the
- 30 development of digital RT-PCR (RT-dPCR) for detection and quantification of measles virus (MeV)
- 31 in wastewater, and application to retained concentrated samples obtained from 28 national sentinel
- 32 SARS-CoV-2 wastewater surveillance sites and 19 localised collection points in a single province
- before, during and after a measles outbreak of over 2,000 laboratory-confirmed cases.

### 34 Methods

35 We validated a RT-dPCR assay incorporating WHO-recommended primers for detection and

- 36 differentiation of wild-type and vaccine genotypes. We applied this to retained wastewater samples
- 37 concentrated by ultrafiltration and stored at -20°C. We compared wastewater findings by district and
- 38 epidemiological weeks with laboratory-confirmed measles case data obtained from national fever-
- rash surveillance for districts with adequate surveillance indicators ( $\geq 2/100,000$  non-measles cases)

## 40 Findings

- 41 Amongst 2,149 wastewater concentrates obtained between 16 February 2021 and 08 March 2024, we
- 42 identified 43 (2%) samples containing MeV RNA in concentrations ranging from 2,04-6,11 genome
- 43 copies/mL. MeV genotype A (vaccine strain) was co-detected in wastewater in 6 instances along with
- 44 non-A (wild-type) genotypes. Comparison of wastewater and clinical fever-rash surveillance data by
- 45 epidemiological week and district identified 27 district-time instances where at least one positive
- 46 wastewater sample was identified, of which 14 (52%) districts reported at least one laboratory-
- 47 confirmed clinical case in that same epidemiological week. Amongst districts with positive
- 48 wastewater samples, wastewater surveillance detected MeV in 13/27 (48%) time-district pairs when
- 49 clinical surveillance failed to detect cases. Amongst district-time instances where at least one
- 50 laboratory-confirmed measles case was detected (N=127), MeV was detected in at least one
- 51 wastewater sample collected in that same epidemiological week in 14 (11%) districts

### 52 **Interpretation**

- 53 Wastewater surveillance may be a useful complementary surveillance tool for identification of
- 54 districts with ongoing measles circulation. MeV detection rates may be improved by real-time testing
- 55 to limit RNA degradation and improved concentration and nucleic acid extraction processes.
- 56 Ongoing wastewater surveillance for MeV should be conducted in order to understand the role of
- 57 WES in measles control and elimination.
- 58 Funding

59 This work was funded by BMGF (INV-049271)

60

#### Introduction 61

Measles, a highly infectious, vaccine-preventable viral infection, is targeted by the World Health 62 Organization (WHO) for elimination by 2030[1]. Measles incidence and mortality have declined 63 dramatically since the year 2000 due to increasing global vaccination coverage from 72% in 2000 to 64 83% in 2022, despite a transient decline in 2021 due to the COVID-19 pandemic.[2] Global measles 65 indicators have decreased from 1,072,800 deaths and 145 cases per million in 2000, to 136,200 deaths 66 67 and 29 cases per million in 2022, of which the largest reduction originates from the WHO-AFRO region (85,417 deaths)[2,3]. Despite these improvements, and recovery of vaccination coverage after the 68 decline during the COVID-19 pandemic, measles is still a leading cause of child death under the age of 69 5 years in low- and middle-income countries[3]. In support of the 2021-2030 strategic framework for 70 71 measles and rubella elimination, ongoing global efforts are in place to control viral transmission[1]. 72 These include the provision of two doses of measles vaccine before the age of 5 years as part of the 73 expanded programme of immunisation (EPI)[4], supplementary immunisation activities (SIAs) every 4-5 years where routine vaccination coverage does not achieve 95% coverage, fever-rash surveillance, 74 75 and rapid, outbreak response[1]. High vaccination coverage and sensitive surveillance systems are vital to achieving elimination.[1] 76

77 As measles elimination targets and dates approach, the WHO and national public health authorities rely increasingly on measles surveillance to support program monitoring.[1] However, clinical measles 78 79 surveillance has several limitations. Firstly, many patients and their care-givers do not seek medical 80 care especially when their clinical presentation is uncomplicated. Secondly, health system factors including clinician awareness, propensity to test and notify, financial allocations for testing, and 81 submission of diagnostic specimens often limit submission of diagnostic specimens[5]. Thirdly, 82 incomplete provision of clinical data (such as date of rash onset and vaccination history) leads to 83 challenges in case classification, contact tracing and outbreak response[6]. Fourthly, urine or throat 84 85 swabs are less frequently submitted for PCR testing, rendering genomic surveillance challenging as the 86 blood submitted for serology testing infrequently contains measles virus (MeV). [7]

The National Institute for Communicable Diseases (NICD) in Johannesburg, South Africa is one of 86 87 accredited World Health Organization Global Measles and Rubella Laboratory Network (GMRLN) 88 89 laboratories and conducts measles testing (IgM and IgG serology, PCR, and sequencing) for South Africa and the southern Africa region.[8] Blood from suspected measles cases (any person with fever, 90 91 rash and one of cough, conjunctivitis or coryza) is submitted by provincial and district health department staff to the NICD. South African surveillance indicators have consistently achieved more than the 92 93 required two non-measles fever-rash cases/100,000, except for 2020, when this threshold was only just attained during the SARS-CoV-2 pandemic. [9] 94

95 Intermittent measles outbreaks have continued to occur over the last 25 years in South Africa, the largest 96 of which led to over 21,000 laboratory-confirmed cases[9–11]. Most recently, an outbreak of over 97 1,383 cases commenced in 2022 following apparent importation of the B3 genotype from immediate neighbours.[12,13] The majority of laboratory-confirmed cases were under 15 years of age, with attack 98 99 rates as high as 31/100,000 in selected age groups and provinces.[12,13] The measles SIA was conducted from February- April 2023 targeting children 1-15 years of age, however only a 54% 100 coverage rate was achieved (personal communication, WHO-AFRO Daudi Peter Manyanga). 101

- 102 Wastewater and environmental surveillance (WES) is presently used to provide highly sensitive surveillance data as part of the WHO-lead global polio elimination initiative (GPEI).[14,15] In 2022 103 and 2023, following widespread uptake of WES to support SARS-CoV-2 and Mpox 104 105 surveillance,[16,17] the WHO issued and subsequently updated guidance to support the implementation of WES as a complementary surveillance tool for SARS-CoV-2 outbreak preparedness 106 and response.[18] On the basis of these global experiences, it has been suggested that WES be applied 107 108 as a surveillance tool for other pathogens targeted for elimination.[19] Whilst a number of groups have 109 developed testing methodologies, [20–23] measles WES has not been implemented as part of routine 110 surveillance or during outbreak response. To date, only Benschkop et al detected MeV in 6/56 (10,7%) 111 wastewater samples collected for polio surveillance during a measles outbreak in a vaccine-hesitant 112 community.[24]
- In 2020, the NICD expanded polio testing at 18 WES sentinel sites to include SARS-CoV-2 across nine 113 provinces of SA.[25] Over time, and dependent on funding, the number and location of sites changed. 114 Presently, the NICD coordinates a national WES sentinel surveillance network comprising sampling 115 sites at 28 wastewater treatment plants (WWTPs) across nine South African provinces and border 116 transit points, and a network of 19 sampling sites located within the catchment areas of three large 117 WWTPs in the densely populated Gauteng Province. [25] In this paper, we describe the development, 118 optimization and validation of a RT-dPCR assay for detection and quantification of MeV in wastewater, 119 120 which we applied to retained concentrated wastewater samples from the national sentinel surveillance network and Gauteng catchment sites. As wastewater samples were collected during the ongoing 121 national measles outbreak that began in October 2022, we compared wastewater findings with clinical 122 123 surveillance data to explore the role of WES as a complementary surveillance tool for programmatic 124 purposes.

#### Methods and methods 125

#### 126 **Study design and context**

We developed and compared RT-qPCR and RT-dPCR assays that detected and differentiated MeV 127 vaccine and wild-type strains. We applied these and a RT-dPCR assay for PMMoV (to normalize MeV 128

129 results relative to fecal contamination) to retained concentrates of wastewater samples collected from

130 the NICD wastewater surveillance network. Presently the network comprises 28 national WWTP

131 sentinel sites and 19 Gauteng sub-catchment inspection holes. Sampling commenced in February 2021

- or later, and progressively included all nine SA provinces (Fig 1). 132
- 133

134 Figure 1. Sampling locations at South African wastewater treatment plants (national sentinel surveillance sites) and in-line sewer sampling sites (sub-catchment areas in City of Tshwane, 135 136 Johannesburg and Ekurhuleni, inset)

137

#### Laboratory methods 138

#### 139 Wastewater sample collection, concentration and storage.

Grab samples of one liter in volume were collected monthly, weekly or biweekly from collection sites 140 and were transported at 4°C to the NICD within 24 hours of collection. On receipt, samples were 141 refridgerated at 4°C, and within 24-48 hours, 200mL of raw sewage was centrifuged at 4650g at 4°C 142 143 for 30 minutes to clarify the sample. Then 70mL of supernatant was centrifuged at 3500g for 15 minutes through a Centricon<sup>®</sup> Plus-70 centrifugal ultra-filter (Merck Millipore, Tullagreen, Ireland). Material 144 retained in the filter was eluted to a concentrate volume of approximately 1 mL. Concentrates were 145 processed immediately for SARS-CoV-2, and the balance was retained at -20 °C for extraction and 146 PCR once MeV and other assays were developed and validated 147

148

149

150

#### 151 Primers and probes for measles and pepper mild mottle virus (PMMoV) detection

152 Measles- and pepper mild mottle virus (PMMoV)-specific primers and probes were identified from previously described methods (Table 1)[26,27]. We then designed primers and probes to detect MeV 153 genotypes dominant in recent South African outbreaks (B3, D8 and H1) and differentiate these from 154 155 vaccine strain (genotype A). These were designed by retrieving partial reference genome sequences coding for the N gene of these genotypes from NCBI. Sequence alignments were performed using 156 MAFFT, and BioEdit was used to identify regions of similarity and difference[28]-[29]. Candidate 157 primers were checked for *in silico* specificity, secondary structure formation, GC content and melting 158 (blast.ncbi.nlm.nih.gov/Blast.cgi) OligoAnalyzer 159 temperature using BLAST and Tool (www.idtdna.com). Final sequences and alignments are shown in Figure 2. Wild-type and vaccine 160 161 probes were created and labeled with ROX and FAM dyes respectively by Integrated DNA Technology 162 (Coralville, Iowa, USA)

#### 163 Table 1. Primers, probes and source references used for PCR detection of measles virus in

#### 164 wastewater samples.

Target	Genes	Primer name	Sequence (5'-3')	Ref
MeV pan	Nucleocapsid	MVN1139	TGGCATCTGAACTCGGTATCAC	Yoshioka N
		MVN1213R	TGTCCTCAGTAGTATGCATTGCAA	(31)
		MVNP1163Probe	TAMRA-CCGAGGATGCAAGGCTTGTTTCAGA	
MeV vaccine (genotype A)	Nucleocapsid	VMA168F	GAGATTGGGGGGGCAAGGAAGAT	In-house primers
		VMA242R	GCATCACTTGCTCTGCTGGGCC	
		VMA190P	FAM-AGGAGGGTCAAACAGAGTCGA-MGB	
MeV wild-type (genotype non-A)	Nucleocapsid	VMB168F	RRGATTRGGGGGGYAAGGARGAY	In-house primers
		VMB242R	RCATCACTTGMTCTGCTRGRYY	
		VMB190P	ROX-AGGAGGGTCARACAGARYCGR	
PMMoV	Unspecified 5' end	PMMOV_END_F	TTC GCA CTG CAC GGA TAA AGT AT	Daire N et al.,2022 (33)
		PMMOV_END_ R	GCC CCA AAT TCA TCT GCT GGA A	
		PMMOV_END_ M	FAM-ACGCTGTCGCTTTGC	

165

166

## Figure 2. Primers and probe design to differentiate measles virus vaccine strain (Edmonston) from wild genotypes (B3, D8, and H1).

#### 169 Digital PCR optimisation and determination of limit of detection

We determined the limit of detection (LOD) (defined as the concentration in genome copies/uL of the 170 lowest dilution that is theoretically detectable when using optimized methods) with a single- and duplex 171 RT-dPCR assay using pan-MeV primers with and without rubella virus (Ruv) primers (not described). 172 In triplicate, we serially diluted the measles RNA-positive control provided by the Global Measles 173 174 Reference Laboratory Network (GMRLN) in 14 two-fold dilutions (neat to 1:16,384) and subjected these to the QIAcuity OneStep Advanced Probe RT-dPCR assay (Qiagen, Hilden, Germany) on 175 QIAcuity® One, 5plex System dPCR platform (Qiagen) using 96-well 8.5k nanoplates. The pan-MeV 176 RT-dPCR master mix contained 3 µL of 4× QIAcuity One-Step Advanced Probe Master Mix, 0.12 µL 177 of 100× One-Step Advanced RT-Mix, 0.6 µL of 20× primer-probe mix MeV (TAMRA), 0.6 µL of 20× 178 RuV primer-probe mix (data not shown) (Cy5) and 1 µL of QIAcuity Enhancer GC. The same master 179

- 180 mix set-up was used for vaccine and wild-type primers and probe reactions. Cycling conditions for RT-
- dPCR were reverse transcription at 50°C for 40 minutes, RT enzyme inactivation at 95°C for 1 minute
- and 45 cycles of annealing & extension at 60°C.

183 Each RNA dilution of the positive control was also tested using RT-qPCR conducted on the Applied

- Biosystems® 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using the
- 185 QIAcuity One-Step Advanced Probe Master Mix. The RT-qPCR master mix contained 4x One-Step
- 186 Advanced Probe Master Mix 6.25  $\mu$ L, 100x One-Step Advanced RT-Mix 0.25  $\mu$ L, 20x primer-probe
- 187 mix MV (TAMRA) 1.25  $\mu$ L, 20x primer-probe mix RV (Cy5) 1.25  $\mu$ L, Enhancer GC 2  $\mu$ L, RNAse-
- 188 free water 6  $\mu$ L.
- 189 Testing of retained wastewater concentrates

Following thawing, retained concentrates were tested in batches of 92 samples. Total nucleic acids were extracted from 200  $\mu$ L of viral concentrate on the 96 KingFisher Flex Purification System (Thermo Fisher Scientific, Waltham, MA USA) using the MagMAX<sup>TM</sup> Wastewater Ultra Nucleic Acid Isolation kit (Thermo Fisher Scientific) according to the manufacturers instructions. Briefly, nucleic acids were captured in 520  $\mu$ L of lysis binding solution before they were washed in 1Ml of Wash 1 and 3 solutions and eluted in 60  $\mu$ L of elution buffer. We used the formula below to determine the genome copy number per mililitre of the original wastewater sample:

197 
$$SC = (C_{rxn} * V_{rxn \ vol.} * (\frac{V_{elute}}{V_{NA}}) * (\frac{V_{total \ conc.}}{V_{conc. \ extracted}})) / V_{sample \ conc.}$$

SC = Sample concentration (gc/ml)198  $C_{rxn}$  = Concentration (gc/µl) obtained from dPCR machine. 199 200  $V_{rxn vol.}$  = Volume (µl) of the PCR reaction. 201  $V_{elute}$  = Total volume (µl) of the extraction elute.  $V_{NA}$  = Volume (µl) of nucleic acids used in the PCR reaction. 202 203  $V_{total conc.}$  = Total volume (µl) of the concentrate. *V<sub>conc. extracted</sub>* = Volume (ml) of concentrate used for extraction. 204  $V_{sample conc.}$  = Volume of the wastewater sample concentrated. 205

206

### 207 Differentiation of wild-type and vaccine strains

After identification of MeV positive wastewater samples, we returned to residual retained concentrates from these samples and subjected them to a second extraction and PCR using the QIAcuity® One, 5plex System (Qiagen, Hilden, Germany) as described above using both vaccine and wild-type primers to determine genotype A (vaccine) vs non-genotype A (wild-type)(31). we used the commercially available OMZYTA® MMR live attenuated vaccine (derived from Enders' attenuated Edmonston strain) and RNA from clinical samples collected during an outbreak in South Africa, as positive controls for vaccine and wild-type respectively,

## 215 Fever-rash surveillance and diagnostic testing

#### 216 2.1.2. Fever-rash surveillance

Blood specimens from persons with suspected measles are transported to NICD on ice, and tested for
the presence of both measles-specific immunoglobulin M (IgM) antibodies using Euroimmun AntiMeasles virus ELISA (IgM), (Euroimmun AG, Luebeck, Germany). In the absence of vaccination
history, NICD surveillance protocols define a laboratory-confirmed case as a positive IgM serologic
test for measles in a person with fever, rash and one of cough, conjunctivitis or coryza.

222

### **Data analysis**

## 224 Comparison of dPCR and qPCR results, determination of limit of detection and indicators of fecal 225 contamination

We conducted a regression comparing qPCR Ct thresholds and dPCR genome copies/reaction for each dilution of the positive control in monoplex (MeV) and duplex (MeV plus RuV) to determine the limit of detection (LoD) and to assist with interpretation of low concentrations of MeV detected by dPCR (Fig 1). We determined the presence and concentration of PMMoV in gc/uL, and determined the ratio

- of MeV:PMMoV
- 231
- 232

Fig 3. PCR reactions using serial dilutions (1:32 to 1:16,384) of control sequences (obtained
from the World Health Organization Global Measles and Rubella Laboratory Network
programme) of measles virus (MeV, red) and MeV duplexed with rubella virus (RuV, blue)
showing (A) genome copies per microlitre of reaction (vertical axis) by dilution, (dilutions 1:32,
1:64, 1:128, 1:256, 1:512 omitted from the insert) and (B) the cycle threshold (vertical axis) and
log of genome copies per microlitre (gc/uL) (horizontal axis). The limit of detection was
determined to be 0,365 gc/uL in duplex reaction with RuV.

240

### 241 2.4.2. Comparison of clinical surveillance and wastewater measles testing data

We grouped and tallied the total number and the number of IgM-positive clinical specimens submitted 242 for testing by epidemiological week of sample collection and district of health facility where the case 243 244 was identified using case-line lists collected as part of national measles fever-rash surveillance. We also grouped and tallied wastewater samples by epidemiological week and district. We merged these clinical 245 and wastewater results by epidemiological week and district and eliminated week-district pairs where 246 no wastewater samples were tested. We defined a 'positive concordant wastewater-clinical pair' as any 247 instance in a given epidemiological-week in a specified district where at least one wastewater sample 248 tested positive for MeV and one case was identified. Conversely we defined a 'negative concordant 249 250 pair' as one where all wastewater and clinical samples tested negative or no clinical samples were

251 submitted. The remaining 'discordant' pairs were those where least one case was detected but all 252 wastewater samples were negative, or vice versa. We determined and described the proportion of 253 concordant and discordant week-district pairs, and presented these in two-by-two tables. In concordant instances, we also determined the relationship between the number of measles cases detected and the 254 255 proportion testing positive with the wastewater levels of MeV in genome copies/mL using simple 256 regression. Given intrinsic weaknesses in measles surveillance (e.g. absent patient health seeking), we investigated and described the discordant instances where MeV was detected in wastewater, but no 257 clinical cases were detected, to identify if clinical cases had been identified in neighbouring districts in 258 the same epidemiological week, or in the same district during the week before or after the positive 259 sample. 260

### 261 Ethics

262 The protocol for this study was reviewed and approved by the University of the Witwatersrand Human

263 Research Ethics Committee (MM220904)

## 264 **Results**

## 265 **RT-dPCR assay optimisation and determination of the limit of detection**

The manufacture's cycling profile recommended extension for 30s was increased to I minute, and the cycling profile increase from 40 to 45 cycles in order to obtain optimal separation of positive and negative partitions on the RT-dPCR platform. Our in-house primers and assay successfully differentiated clinical MeV strains from vaccine strain (see Supplement). Following optimization of MeV and multiplex MeV and RuV qPCR and dPCR protocols, we determined the relationship between the number positive dPCR partitions and Ct values of qPCR (Fig 1). The limit of detection was determined to be 0,365 gc/uL in duplex reaction with RuV.

273

274

276

## **Testing of retained concentrates from wastewater samples**

A total of 2,149 wastewater concentrates had been stored after processing of grab samples collected 277 278 across nine provinces between 16 February 2021 and 08 March 2024. Wastewater samples from 279 Limpopo, Mpumalanga, NorthWest and the Northern Cape provinces accounted for 58/2149 (2,6%) as sampling from these sites commenced in November 2023-January 2024, or ceased in May 2022 280 281 (Northern Cape Province). Retained concentrates underwent extraction and duplex MeV and RuV 282 (results not presented here) PCR in batches from November 2023 to March 2024. Of the total, 43 samples (2%) tested positive for MeV (Table 2). The majority of wastewater samples were collected 283 in Gauteng province (n=1492), which also had the highest percentage of samples positive for MeV (31, 284 2,1%, Table 2). No MeV was detected in wastewater from the provinces with the lowest numbers of 285

286 tested samples (Table 1). Over the two year period, the majority of positive samples were identified in 2024 (Fig 2, Fig S2). Amongst 42 samples undergoing PCR genotyping, 6 tested positive for both A 287 (vaccine) and non-A (wild-type) genotypes, whilst 36 tested positive for non-A (wild-type) genotype 288 289 only. All but one sample with vaccine strain detected were collected in Gauteng province, and all were collected at least one month after completion of the national outbreak response SIA. The median MeV 290 concentration amongst positive samples was 2,12 (2,04-2,25) gc/mL, and the median ratio of 291 292 MeV:PMMoV was 441x10<sup>-3</sup> (range 276x10<sup>-3</sup> -1528x10<sup>-3</sup>). 293

#### Table 2: The number of samples tested for MeV by province (and district of Gauteng Province) 294

together with the number and proportion testing positive and the range of genome copies/uL amongst 295

296 positive samples. All samples tested positive for crAssphage, and the range of quantitative results in

- 297 genome copies/uL is also provided.
- 298

Province	District	Time period		MeV (#	MeV (# positive	MeV gc/mL (median O1 -	PMMoV gc/mL	Ratio MeV:PMMoV	
	DISTICT	Date from	Date to	tested)	%)	Q3)	(median, Q1-Q3)	x10 <sup>-3</sup> (median, Q1-Q3)	
Eastern Cape	Buffalo City and Nelson Mandela Metro	April 2021	March 2024	187	3 (1.6)	2,12 (2,05-6,4)	404 (346-504)	7,37 (5,33-16,9)	
Free State	Mangaung	August 2021	March 2024	183	3 (1,6)	2,17 (2,07-4,12)	310 (155-548)	11,17 (6,96-15,37)	
Gauteng	City of Tshwane	April 2021	March 2024	637	13 (2)	2,12 (2,08-6,11)	1017 (338-2871)	3,27 (1,11-8,04)	
Gauteng	City of Ekurhuleni	April 2021	March 2024	547	13 (2.4)	2,11 (2,04-2,19)	442 (316-1421)	5,54 (1,43-15,78)	
Gauteng	City of Johannesburg	April 2021	March 2024	308	5 (1.6)	2,14 (2,11-2,16)	177 (123-199)	11,29 (10,96-17,49)	
KwaZulu- Natal	eThekwini	August 2021	March 2024	149	5 (3,4)	2,04 (2,04-4,17)	1079 (387-2343	4,08 (0,87-5,27)	
North West	Bojanala	November 2023	March 2024	22	0	-	1231 (653-1914)	-	
Northern Cape	Namakwa	August 2021	May 2022	14	0	-	927 (505 - 105)	-	
Western Cape	City of Cape Town	August 2021	March 2024	72	1 (1.4)	2.1*	1934	1,1	
Mpumalanga	Ehlanzeni	February 2024	March 2024	10	0	-	616 (217- 821)	-	
Limpopo	Mopani	February 2024	March 2024	12	0	-	370 (201 - 740)	-	
South Africa		April 2021	March 2024	2149	43 (2)	2,12 (2,04-2,25)	441 (276-1528)	5,27 (1,37-15,72)	

299

300

301

- 302 Fig 4: Epidemiological curve showing the number clinical cases submitted to the National
- 303 Institute for Communicable Diseases as part of fever-rash surveillance that tested positive for
- 304 measles IgM (blue bars) and the number of positive wastewater samples (orange or green) by
- epidemiological week (2021, week 52, to 2024, week 10) from A) the entire South Africa, and B) 305
- 306 **Gauteng Province**
- 307
- 308
- 309

#### Comparison of clinical surveillance data with wastewater MeV samples. 310

For each district, the number and proportion of wastewater samples testing positive over the period of 311 observation ranged from 0 to 40% (week 12, 2023 Ekurhuleni Metropole) as seen in Fig 2A&B and S2. 312 We identified 481 epidemiological week-districts where both wastewater samples and clinical 313 diagnostic tests were submitted for surveillance. Amongst week-districts, some districts had multiple 314 wastewater samples (median=2, range 1-19 samples) for a given week from a number of sampling 315 316 locations (n=1-7), and 357 week-district pairs had more than one positive clinical case per week, 317 ranging from 1-104 cases, with a median of 3 cases per week.

318 Amongst all week-district pairs, measles was identified in the week-district by both wastewater and clinical surveillance in 2.9% (14) pairs, or, by neither wastewater and clinical surveillance in 343 (71%) 319 of pairs (Table 3). Discordance was observed in the remaining 124 (25.8%) of week-district pairs of 320 321 which the larger proportion (23.1%) were those with negative wastewater samples in districts where clinical cases were detected. When the time frame for a concordant positive test was broadened to 322 include the presence of clinical cases up to a week before or after a positive wastewater sample, the 323 324 number of clinical-wastewater time-district pairs where wastewater tested positive and clinical cases were detected increased to 17 (3.5%), whilst the number of time-district pairs where wastewater 325 detected evidence of measles and clinical surveillance failed to detect a case, decreased to 10 (2.1%, 326 327 Table 3). Amongst concordant wastewater and clinical week-district pairs, there was no discernable relationship between number of cases and measles genome copies/ml in wastewater. Amongst 328 329 discordant week-district pairs where MeV was detected in wastewater (Table 4), no clinical testing was 330 conducted in nine districts during that week, whilst 1-15 laboratory-confirmed cases of measles were 331 identified in eight of 14 neighbouring districts.

For both wastewater and clinical surveillance, results were considered positive if one or more specimens 332 333 or samples tested positive in that epidemiological week, and negative if no specimens or samples tested positive. In part A, clinical results were evaluated for the same epidemiological week as wastewater 334 results. In part B, clinical results from the previous, same and next epidemiological week were 335 considered together and compared with wastewater results for a specific week, in order to accommodate 336 337 for a 7-14 day measles incubation period. No dose-relationship was discernable between the

- 338 concentration of MeV detected in wastewater and the number of laboratory-confirmed cases in the same
- district and epidemiological week (Figure S2)
- 340
- 341 Table 3. A comparison of wastewater and clinical testing results in the same district and
- epidemiological week for surveillance conducted between epidemiological week 7, 2021 to
- 343 epidemiological Week 10, 2024.

Part A: same epidemiological		Wastewater Results					
week		Positive	Negative	Total			
Clinical	Positive (IgM)	14 (2.9%)	111 (23.1%)	125			
Results (IgM)	Negative (IgM)	13 (2.7%)	343 (71.3%)	356			
	Total	27	454	481*			
Part B: same epidemiological		Wastewater Results					
week + clin	nical results one	Positive	Negative	Total			
week befor	e and one after		-				
Clinical	Positive (IgM)	17 (3.5%)	190 (39.5%)	207			
Results (IgM)	Negative (IgM)	10 (2.1%)	264 (54.9%)	274			
(0,	Total	27	454	481			

344

345 Table 4. Fever-rash surveillance results for epidemiological weeks and districts where wastewater

#### 346 samples tested positive for measles RNA during epidemiological week 7, 2021 to epidemiological

347 Week 10, 2024. Epidemiological weeks are designated with the year followed by the week number.

<b></b>		District under	• observation	Clinical cases in neighbouring districts			
Epidemiological week	District	Wastewater (positive/total)	Clinical (IgM +/total)	Cases in that week	Cases the week before	Cases the week after	
2021-W45	Ekurhuleni	1/2		0	0	0	
2021-W45	Tshwane	1/2		0	0	0	
2022-W04	Buffalo city	1/2		0	0	0	
2022-W04	Ekurhuleni	1/2	0/2	2	0	2	
2022-W05	Ethekwini	1/2		0	0	0	
2022-W07	Buffalo city	1/2	1/2 .		0	0	
2022-W18	Tshwane	1/2	0/2	1	0	1	
2022-W42	Ekurhuleni	1/2		5	4	5	
2023-W12	Ethekwini	Ethekwini 1/1 0/6 0		0	1	1	
2023-W12	Mangaung 1/2 0/2 4		4	1	1		
2023-W15	Ekurhuleni	1/1 0/1		15	15	7	
2023-W20	Johannesburg	1/6			12	12	
2023-W25	Ethekwini	1/1		0	0	0	
2023-W33	Ekurhuleni	1/5	0/1	7	4	9	
2023-W37	Buffalo city	1/4		0	0	0	

	2023-W37	Ekurhuleni	1/10	0/1	2	9	12
348							
349							

350

#### 4. Discussion 351

Retrospective testing of retained wastewater concentrates sampled from national and sentinel site 352 353 surveillance during an ongoing measles outbreak in South Africa detected MeV RNA at copy numbers ranging from 1,97 - 165,8 gc/mL in 43 (2%) of wastewater samples. We observed positive MeV 354 wastewater detections in health districts where no cases were detected. Despite likely RNA decay on 355 account of sample storage, our results illustrate the usefulness of this surveillance modality, and suggest 356 357 that real-time wastewater surveillance should be conducted together with clinical surveillance to determine the sensitivity of MeV WES and to develop appropriate public health responses to wastewater 358 359 findings.

For a number of reasons, we believe that detection of MeV in wastewater is representative of measles 360 361 infections in the catchment area and district and has public health significance. Firstly, MeV is excreted in urine for up to 14 days post vaccination, [30] and will therefore be present in wastewater following 362 wild-type infection. Secondly, viruses from point sources may be detectable in sewage networks for 363 several days after shedding ceases on account of dispersion due to differing gradients, varying flow 364 rates and entrapment in sediment.[31] Thirdly, a positive finding of MeV in wastewater samples even 365 366 at low copy numbers, is likely to be true, as we demonstrated validity of low copy numbers by testing 367 serial dilutions of positive controls by qPCR and dPCR. Fourthly, MeV has been detected in wastewater in an outbreak context.[24] and in low copy numbers ranging from 2-22 genome copies per 368 369 milliliter[23]. Fifthly, in our study, laboratory-confirmed measles cases were detected in 14/27 (52%) districts where wastewater tested positive for MeV. MeV negative results in the remaining districts may 370 371 be explained by the intrinsic limitations of wastewater detection for viral RNA targets (such as viral 372 decay in wastewater matrix, and/or excessive dilution, or timing of sampling), geographical mismatch between case location and wastewater catchment area, or due to prolonged storage of concentrates at -373 20°C. Lastly, the finding of MeV in wastewater when clinical surveillance fails to identify cases 374 375 indicates potential for measles outbreaks in our context where vaccination coverage is reportedly less 376 than 95%.

Several limitations are evident from our findings. Sample storage and wastewater concentration 377 378 methods (ultrafiltration) may have contributed to low viral recovery rates and concentrations[32]. Real 379 time processing and newer concentration-extraction methodologies may enhance detection rates. 380 Despite wastewater sample collection during an outbreak (October 2022 and ongoing) and subsequent

381 12 week vaccination campaign (February to April 2023), we identified vaccine genotype in only 6 382 samples, all of which were collected outside the campaign window. RNA decay, and viral dynamics in 383 wild-type infection vs vaccine inoculation, coupled with vaccination of largely immune persons may account for this. This may account for the absence of a dose-response relationship between the 384 385 concentration of MeV detected in wastewater and the number of laboratory-confirmed cases in the same 386 district and epidemiological week. Lastly, in the context of the coupling of measles and rubella vaccine and combined programmatic goals, there is merit in using a multiplex assays for WES detection of 387 measles and rubella wild-type and vaccine strain detection. Our assays, whilst multiplexed with RuV, 388 389 did not include vaccine-specific primers and probes for either virus. The inclusion of vaccine-strainspecific primers and probes in the detection assay would facilitate interpretation of results and support 390 391 immediate public health action. Lastly, there is no available evidence at this moment to support the need for normalizing PCR targets relative to population size using fecal indicators, flow rates or 392 393 combinations thereof for MeV detection. All our retained samples tested positive for PMMoV at high 394 genome copies/uL, indicating the presence of fecal contamination.

395 Optimal public health responses to detection of MeV in wastewater in the absence of clinical cases need 396 careful consideration. Following detection of clinical cases, WHO presently recommends case 397 investigation and diagnostic testing, contact tracing with ring vaccination, case finding, and district 398 wide supplementary immunization activities (SIA) if a threshold of cases (two to five cases per health district per month) are identified.[33] Our approach to analysis of our findings, namely a comparison 399 of wastewater and clinical surveillance data at a district level by epidemiological week, is informed by 400 biological parameters of measles infection and WHO guidelines regarding public health responses to 401 402 measles cases as follows: the incubation period of measles is 1-2 weeks, and current surveillance 403 guidelines suggest a threshold of 2-5 cases *per district* in one month before initiating appropriate public health interventions[34]. Therefore, assessment of wastewater detection vs cases per week in a given 404 405 geographical area may provide forewarning of incubating cases, and support heightened surveillance as a minimum public health response. However, as the sensitivity of WES MeV surveillance becomes 406 407 clearer, and given the elimination agenda, it may become evident that WES MeV detection should 408 trigger a supplementary immunization activity.

409 Our findings suggest that real-time WES for measles holds promise to support the global measles and 410 rubella elimination agendas. WES may complement clinical surveillance or be used as the only 411 surveillance modality in contexts with limited access to diagnostic testing. Evaluation of more efficient 412 concentration, extraction and detection methods to improve sensitivity and provide sufficient material 413 for genotyping are desirable. Integration of real-time MeV WES together with clinical surveillance 414 may allow for sensitivity estimations and insight into public health actions following detection of 415 wastewater.

#### 416

## 417 Acknowledgements

We would like to acknowledge the contribution of the NICD Centre for Vaccines and Immunology for use of the polio environmental laboratory, and measles surveillance data (also approved by Wits HREC). We thank the municipal workers, and NICD drivers who collected and transported certain wastewater samples. We thank our sample collectors Lebohang Rabotapi, Lethabo Monametsi, and laboratory technicians Thabo Mangena, Mantshali Motloung for collecting and initial processing of the samples, and our administrator Namhla Madikane for her helpful support and willingness to go to the field when necessary.

425

## 426 Supplementary material

427

428

Figure S1. Epidemiological curves by province of South Africa showing the number of IgM positive cases submitted to the National Institute for Communicable Diseases as part of feverrash surveillance and the number of positive wastewater samples (green) by epidemiological

432 week (2021, week 52, to 2024, week 10)

Figure S2. The number of laboratory-confirmed measles cases (vertical axis) by the number of genome copies of measles virus per millilitre of wastewater (horizontal axis) in wastewater collected from a sample collection point in the district where the measles case was identified

- collected from a sample collection point in the district where the measles case was identified
   (n=43)
- 437
- 438
- 439

440

## 441 **References**

442 1. WHO. Measles and Rubella Strategic Framework: 2020-2030. Geneva: WHO; 2020. Available:
443 https://www.who.int/publications/i/item/measles-and-rubella-strategic-framework-2021-2030

Dixon MG, Ferrari M, Antoni S, Li X, Portnoy A, Lambert B, et al. Progress Toward Regional Measles
Elimination - Worldwide, 2000-2020. MMWR Morb Mortal Wkly Rep. 2021;70: 1563–1569.
doi:10.15585/mmwr.mm7045a1

447 3. Minta AA, Ferrari M, Antoni S, Portnoy A, Sbarra A, Lambert B, et al. Progress Toward Measles
448 Elimination - Worldwide, 2000-2022. MMWR Morb Mortal Wkly Rep. 2023;72: 1262–1268.
449 doi:10.15585/mmmr.22462

doi:10.15585/mmwr.mm7246a3

450 4. Measles vaccines: WHO position paper – April 2017. Releve Epidemiol Hebd. 2017;92: 205–227.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.01.24312904; this version posted September 2, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

- 451 5. Patel MK, Gibson R, Cohen A, Dumolard L, Gacic-Dobo M. Global landscape of measles and rubella surveillance. Vaccine. 2018;36: 7385-7392. doi:10.1016/j.vaccine.2018.10.007 452
- 453 Orenstein WA, Hinman A, Nkowane B, Olive JM, Reingold A. Measles and Rubella Global Strategic 6. 454 Plan 2012-2020 midterm review. Vaccine. 2018;36 Suppl 1: A1–A34. doi:10.1016/j.vaccine.2017.09.026
- 455 7. Hübschen JM, Gouandjika-Vasilache I, Dina J. Measles. Lancet Lond Engl. 2022;399: 678-690. 456 doi:10.1016/S0140-6736(21)02004-3
- 457 World Health Organization. Manual for the laboratory-based surveillance of measles, rubella, and 8. 458 congenital rubella syndrome. Geneva, Switzerland; 2018. Available: https://www.who.int/immunization/ 459 monitoring surveillance/burden/laboratory/manual/en/
- 460 9. Yousif M, Hong H, Malfeld S, Smit S, Makhathini L, Motsamai T, et al. Measles incidence in South 461 Africa: a six-year review, 2015-2020. BMC Public Health. 2022;22: 1647. doi:10.1186/s12889-022-14069-w
- 462 10. McMorrow ML, Gebremedhin G, van den Heever J, Kezaala R, Harris BN, Nandy R, et al. Measles outbreak in South Africa, 2003-2005. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. 2009;99: 314-319. 463
- 464 Ntshoe GM, McAnerney JM, Archer BN, Smit SB, Harris BN, Tempia S, et al. Measles outbreak in 11. 465 South Africa: epidemiology of laboratory-confirmed measles cases and assessment of intervention, 2009-2011. 466 PloS One. 2013;8: e55682. doi:10.1371/journal.pone.0055682
- 467 12. National Institute for Communicable diseases. South African Measles Outbreak Update, 2023.
- 468 Johannesburg, South Africa: National Institute for Communicable Diseases; 2023 Jun. Available: 469 https://www.nicd.ac.za/south-african-measles-outbreak-update-2023-2-june-2023/
- 470 13. National Institute for Communicable diseases. Measles and Rubella Monthly Surveillance Report, 8 471 April 2024. Johannesburg, South Africa: National Institute for Communicable Diseases; 2024 Apr. Available: 472 https://www.nicd.ac.za/measles-and-rubella-monthly-surveillance-report-08-april-2023/
- 473 14. Global polio elimination initiative. Polio Eradication Strategy 2022-2026: Delivering on a Promise. 474 WHO; 2022. Available: https://polioeradication.org/gpei-strategy-2022-2026/
- 475 15. O'Reilly KM, Verity R, Durry E, Asghar H, Sharif S, Zaidi SZ, et al. Population sensitivity of acute 476 flaccid paralysis and environmental surveillance for serotype 1 poliovirus in Pakistan: an observational study. 477 BMC Infect Dis. 2018;18: 176. doi:10.1186/s12879-018-3070-4
- 478 Kilaru P, Hill D, Anderson K, Collins MB, Green H, Kmush BL, et al. Wastewater Surveillance for 16. 479 Infectious Disease: A Systematic Review. Am J Epidemiol. 2023;192: 305-322. doi:10.1093/aje/kwac175
- 480 17. Wolfe MK, Yu AT, Duong D, Rane MS, Hughes B, Chan-Herur V, et al. Use of Wastewater for Mpox 481 Outbreak Surveillance in California. N Engl J Med. 2023;388: 570-572. doi:10.1056/NEJMc2213882
- 482 18. WHO. Environmental surveillance for SARS-CoV-2 to complement other public health surveillance. 483 Geneva, Switzerland; 2023. Available: https://www.who.int/publications/i/item/9789240080638
- 484 19. Shaw AG, Troman C, Akello JO, O'Reilly KM, Gauld J, Grow S, et al. Defining a research agenda for 485 environmental wastewater surveillance of pathogens. Nat Med. 2023;29: 2155-2157. doi:10.1038/s41591-023-486 02457-7
- 487 20. Hayes EK, Gouthro MT, LeBlanc JJ, Gagnon GA. Simultaneous detection of SARS-CoV-2, influenza 488 A, respiratory syncytial virus, and measles in wastewater by multiplex RT-qPCR. Sci Total Environ. 2023;889: 489 164261. doi:10.1016/j.scitotenv.2023.164261
- 490 21. Wu J, Wang MX, Kalvapalle P, Nute M, Treangen TJ, Ensor K, et al. Multiplexed detection, 491 partitioning, and persistence of wild type and vaccine strains of measles, mumps, and rubella viruses in 492 wastewater. medRxiv; 2024. p. 2024.05.23.24307763. doi:10.1101/2024.05.23.24307763
- 493 22. Kevill JL, Lambert-Slosarska K, Pellett C, Woodhall N, Richardson-O'Neill I, Pântea I, et al. 494 Assessment of two types of passive sampler for the efficient recovery of SARS-CoV-2 and other viruses from 495 wastewater. Sci Total Environ. 2022;838: 156580. doi:10.1016/j.scitotenv.2022.156580

medRxiv preprint doi: https://doi.org/10.1101/2024.09.01.24312904; this version posted September 2, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

496 23. Rector A, Bloemen M, Hoorelbeke B, Ranst MV, Wollants E. Detection of measles virus genotype D8 497 in wastewater of Brussels capital region, Belgium, March 2024. medRxiv; 2024. p. 2024.04.08.24305478. 498 doi:10.1101/2024.04.08.24305478

499 24. Benschop KSM, van der Avoort HG, Jusic E, Vennema H, van Binnendijk R, Duizer E. Polio and 500 Measles Down the Drain: Environmental Enterovirus Surveillance in the Netherlands, 2005 to 2015. Appl 501 Environ Microbiol. 2017;83: e00558-17. doi:10.1128/AEM.00558-17

502 25. NICD. Wastewater-based epidemiology for SARS-CoV-2 surveillance in South Africa - weekly report. 503 Johannesburg, South Africa: NICD; 2024 Epidemiological week. Available: https://www.nicd.ac.za/diseases-a-504 z-index/disease-index-covid-19/surveillance-reports/weekly-reports/wastewater-based-epidemiology-for-sars-505 cov-2-in-south-africa/

506 Yoshioka N, Hagiya H, Deguchi M, Hamaguchi S, Kagita M, Tomono K. Simultaneous and rapid 26. 507 detection method for measles and rubella using single-tube multiplex real-time quantitative RT-PCR. J Infect 508 Chemother Off J Jpn Soc Chemother. 2019;25: 829-831. doi:10.1016/j.jiac.2019.05.005

509 27. Cantillon D, Roberts AP. Development and evaluation of TaqMan-based, one-step, real-time RT-PCR 510 assays for pepper mild mottle virus detection for near source tracking and wastewater-based epidemiology 511 validation. PloS One. 2022;17: e0278784. doi:10.1371/journal.pone.0278784

512 28. Yamada KD, Tomii K, Katoh K. Application of the MAFFT sequence alignment program to large 513 data—reexamination of the usefulness of chained guide trees. Bioinformatics. 2016;32: 3246–3251. 514 doi:10.1093/bioinformatics/btw412

515 29. Carlsblad, C. H T. BioEdit: An important software for molecular biology. GERF bulletin of 516 Biosciences. 2011;2: 60-61.

517 30. Rota PA, Khan AS, Durigon E, Yuran T, Villamarzo YS, Bellini WJ. Detection of measles virus RNA 518 in urine specimens from vaccine recipients. J Clin Microbiol. 1995;33: 2485-2488. doi:10.1128/jcm.33.9.2485-519 2488.1995

520 Hovi T, Stenvik M, Partanen H, Kangas A. Poliovirus surveillance by examining sewage specimens. 31. 521 Quantitative recovery of virus after introduction into sewerage at remote upstream location. Epidemiol Infect. 522 2001;127: 101-106. doi:10.1017/s0950268801005787

523 32. Rusiñol M, Martínez-Puchol S, Forés E, Itarte M, Girones R, Bofill-Mas S. Concentration methods for 524 the quantification of coronavirus and other potentially pandemic enveloped virus from wastewater. Curr Opin 525 Environ Sci Health. 2020;17: 21-28. doi:10.1016/j.coesh.2020.08.002

526 33. WHO. Measles outbreak guide. Geneva, Switzerland: WHO; 2022. Available: 527 https://www.who.int/publications/i/item/9789240052079

528 34. WHO. WHO African Regional measles and rubella surveillance guidelines. WHO AFRO; 2015.

529 Available: https://www.afro.who.int/publications/who-african-regional-measles-and-rubella-surveillance-530 guidelines-0

531

		Forward Primer	Probe				ſ	Reverse Primer	
	1400	1410	420 1430	144	1450	1460 1	470	1480	1490
	1		]	<b>I</b> .			1.		
AF266288.2 Edmonston	accgagat	tggggggcaaggaaga	aggagggtcaaacaga	gtogag	gagaagccagggaga	gctacagagaaaa	cg	geccagcagagcaagt	gatge
MN893225.1 Measles B3	gc	tg		ac		c			
OR290098.1 Measles B3	g	tq	a.	ac		c		1t	
OR290098.1 Measles B3	g	tq	a.	ac	c	c		t	
XX838946.2 Measles B3	g	tg		ac	c	c			
PP998307.1 Measles D8	ag		q	t.q.	q	a		ttt	
MF496200.1 Measles D8	ag		q	q.	q	a		ttt	
MF496201.1 Measles D8	ag		q	d.	q	a		ttt	
MH356237.1 Measles D8	gag			d.		.tagtgt		.tttg	
MZ483930.1 Measles H1	g		a		.ga	ac		q	
MZ483937.1 Measles H1	g		a		.ga	ac		q	
KJ755976.1 Measles H1	g		a		.ga	ac		q	
KJ755979.1 Measles H1	a		a		.ga	a		a	

Figure X. Primers and probe design to differentiate measles virus vaccine strain (Edmonston) from wild genotypes (B3, D8, and H1).



Figure S1. Sampling locations at South African wastewater treatment plants (national sentinel surveillance sites) and in-line sewers (case-study sub-catchment areas in City of Tshwane, Johannesburg and Ekurhuleni, inset)



В



Figure 1. Graphs constructed for PCR reactions using serial dilutions (1:32 to 1:16,384) of control sequences (obtained from the World Health Organization Global Measles and Rubella Laboratory Network programme) of measles virus (MeV, red) and MeV duplexed with rubella virus (RuV, blue) showing (A) genome copies per microlitre of reaction (vertical axis) by dilution, (dilutions 1:32, 1:64, 1:128, 1:256, 1:512 omitted from the insert) and (B) the cycle threshold (vertical axis) and log of genome copies per microlitre (gc/uL) (horizontal axis). The limit of quantification was determined to be 0,365 gc/uL in duplex reaction with RuV.





Figure 2. Epidemiological curve showing the number of IgM positive cases submitted to the National

Institute for Communicable Diseases as part of fever-rash surveillance (blue bars) and the number of positive wastewater samples (orange or green) by epidemiological week (2021, week 52, to 2024, week 10) from A) the entire South Africa, and B) Gauteng province





Figure S2. Epidemiological curves by province of South Africa showing the number of IgM positive cases submitted to the National Institute for Communicable Diseases as part of fever-rash surveillance and the number of positive wastewater samples (green) by epidemiological week (2021, week 52, to 2024, week 10)



Figure S3. The number of laboratory-confirmed measles cases (vertical axis) by the number of genome copies of measles virus per millilitre of wastewater (horizontal axis) in wastewater collected from a sample collection point in the district where the measles case was identified (n=43)

# Figure S2